Study on Fenofibrate’s Effects in Treating Gout in Type 2 Diabetic Patients

Understanding Gout and Its Treatment Goals

Gout is a condition marked by joint inflammation, leading to painful episodes that can persist for days to weeks. This inflammation occurs when urate crystals accumulate in the joints due to elevated blood uric acid levels. The primary treatment objectives focus on minimizing the frequency, intensity, and duration of gout attacks by maintaining lower uric acid levels in the bloodstream.

The Role of Fenofibrate

Fenofibrate is a medication primarily used to manage cholesterol levels, and it also addresses certain diabetes complications. Notably, there have been reports indicating that fenofibrate can lower uric acid levels, potentially leading to gout remission.

Research Overview

A recent study published in The Lancet Diabetes and Endocrinology examined the impact of fenofibrate on uric acid levels and gout attack frequency among type 2 diabetics. Conducted in New Zealand, this randomized, double-blind controlled trial compared fenofibrate treatment to a placebo. Participants aged 50 to 75 with type 2 diabetes were recruited from clinical sites in Australia, New Zealand, and Finland, with a median follow-up of five years involving regular outpatient visits. Researchers evaluated changes in uric acid blood concentrations and the occurrence of gout attacks as primary outcomes.

Findings: Uric Acid Level Reduction

The study demonstrated a significant reduction in uric acid levels, with a 20.2% decrease in the fenofibrate group after six weeks of treatment. After one year, uric acid levels remained approximately 20% lower in this group compared to the placebo. This decrease was consistent across all subgroups, with no distinctions noted between genders. Notably, the treatment was more effective in patients with higher baseline uric acid levels. Even among patients already receiving allopurinol, a common gout preventative, fenofibrate contributed to a significant reduction in uric acid levels, albeit to a lesser extent than in those not on allopurinol.

Reduction in Gout Attack Incidence

A crucial outcome of the study was the nearly 50% reduction in the incidence of gout attacks among participants receiving fenofibrate over the five-year period. Additionally, the drug was well tolerated, showing a safety profile comparable to that of the placebo, with no increase in renal stone events among fenofibrate users. The robustness of these findings was confirmed through adjustments for potential confounders, and the large participant pool effectively represented the type 2 diabetic population, enhancing the clinical applicability of the results.

Conclusion: Fenofibrate as a Potential Gout Treatment

The findings align with previous short-term studies on fenofibrate’s effects on uric acid and gout. However, this study uniquely illustrates the sustained impact of fenofibrate on both uric acid reduction and gout attack frequency. In summary, the research suggests that fenofibrate may serve as a valuable addition to gout treatment protocols for patients with diabetes.

Reference

Waldman, B., Ansquer, J., Sullivan, D. R., Jenkins, A. J., Mcgill, N., Buizen, L., … Keech, A. C. (2018). Effect of fenofibrate on uric acid and gout in type 2 diabetes: A post-hoc analysis of the randomised, controlled FIELD study. The Lancet Diabetes & Endocrinology, 6(4), 310-318. doi:10.1016/s2213-8587(18)30029-9